Evaluation of in vivo efficacy in mouse models. (A) Survival of mice in a disseminated Burkitt lymphoma xenograft model was compared for veltuzumab treatment via intraperitoneal versus subcutaneous administration. SCID mice were administered 1.5 × 107 Daudi cells intravenously on day 0. Therapy with veltuzumab began on day 1 with mice receiving either a single intraperitoneal or single subcutaneous injection of veltuzumab at does of 60, 20, or 5 μg. Control mice received an intraperitoneal injection of either saline or 60 μg hMN-14 IgG (labetuzumab, anti-CEACAM5 isotype-matched antibody). (B) The minimal effective dose of veltuzumab was determined in a disseminated Burkitt lymphoma xenograft model. SCID mice were administered 1.5 × 107 Daudi cells intravenously on day 0. Therapy with veltuzumab began on day 1 with a single intraperitoneal injection of veltuzumab. Doses administered were 0.5, 0.25, 0.1, or 0.05 μg veltuzumab. Control mice received a 200-μL intraperitoneal injection of saline. (C) Survival of mice bearing disseminated follicular cell lymphoma was examined for treatment with decreasing doses of veltuzumab. SCID mice were administered 2.5 × 106 WSU-FSCCL cells intravenously on day 0. On day 5, mice received a single intraperitoneal injection of veltuzumab at a dose of 35, 3.5, 0.35, or 0.035 μg. Control mice received only saline.
